All Posts By

Smartkarma Daily Briefs

Daily Brief Industrials: Kawasaki Heavy Industries, DH Shipbuilding, Mazagon Dock Shipbuilders , Yangzijiang Shipbuilding, Heg Ltd, Norfolk Southern, Oxley Holdings, MMC Port Holdings Berhad, Asian Pay Television Trust, Magellan Aerospace and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Kawasaki Heavy (7012 JP): Cheaper than Peers with Index Inclusion Kicker
  • DH (Daehan) Shipbuilding IPO Book Building Results Analysis
  • NIFTY NEXT50 Index Rebalance Preview: Potential Changes & Close Names
  • Which Dividend Diamonds Will Sparkle?
  • HEG IN – Graphite Leader Expands into Anodes; Capacity Edge and Battery Optionality Key
  • Union Pacific Eyes Norfolk Southern: Is America’s First Coast-to-Coast Rail Giant Taking Shape?
  • Markets in Motion: Turnover Gains Spark Sharper Spreads
  • MMC Ports Pre-IPO – Monetization Event for Promoters
  • Aberdeen Extends CLINT Deemed Interest to 6%
  • Small-Caps Positioned to Benefit from Multi-Year Defence Spending Cycle


Kawasaki Heavy (7012 JP): Cheaper than Peers with Index Inclusion Kicker

By Brian Freitas

  • Kawasaki Heavy Industries (7012 JP) stock price has moved higher over the last few months, and the increased market cap should result in global index inclusion in August.
  • Kawasaki Heavy Industries (7012 JP) has underperformed its larger peers, and the stock is trading cheaper than the average of its peers on most metrics. 
  • There will be positioning in the stock that has been built up over the last month and a relative value trade could offer better risk reward here.

DH (Daehan) Shipbuilding IPO Book Building Results Analysis

By Douglas Kim

  • DH Shipbuilding reported a solid IPO book building results analysis. The IPO price has been finalized at 50,000 won per share (high end of the IPO price range).
  • At the IPO price of 50,000 won, the expected market cap will be 1.9 trillion won. DH Shipbuilding will start trading on 1 August. 
  • Our base case valuation of DH Shipbuilding is target price of 67,576 won per share, which represents a 35% upside to the IPO price.

NIFTY NEXT50 Index Rebalance Preview: Potential Changes & Close Names

By Brian Freitas

  • With the review period nearing completion, there could be 4 changes (including 1 migration) for the NSE Nifty Next 50 Index (NIFTYJR INDEX) in September.
  • There is one stock close to inclusion zone and one stock close to deletion zone and price movements over the rest of the month will determine the final changes.
  • Estimated one-way turnover is 7.8% resulting in a one-way trade of INR 30.06bn (US$350m). Six of the eight potential changes will have over 2x ADV to trade from passive trackers.

Which Dividend Diamonds Will Sparkle?

By GEMS Research – Aletheia Capital

  • Singapore’s yield superiority is not restricted to the REIT and Banking Sectors.
  • There are 13 stocks (that are not REITs or Banks) that have been identified as high performing dividend stocks.
  • These stocks trade more than US$3m ADT in the last six months and are outside the REIT and Banking sectors. 

HEG IN – Graphite Leader Expands into Anodes; Capacity Edge and Battery Optionality Key

By Rahul Jain

  • Q4 FY25 delivered best operational quarter with 27% EBITDA margin and steady 80–85% utilization despite global steel demand weakness.
  • Expanding graphite electrodes to 100 ktpa, commissioning 20 ktpa anode plant by FY27, and deepening exposure via GrafTech stake.
  • Base case SOTP implies Rs614/share, valuing core at 8× EV/EBITDA and anode business at 2.5× invested capital.

Union Pacific Eyes Norfolk Southern: Is America’s First Coast-to-Coast Rail Giant Taking Shape?

By Baptista Research

  • Norfolk Southern Corp. has emerged as a potential acquisition target for Union Pacific Corp., with early-stage discussions underway that could reshape the North American rail landscape.
  • If the deal materializes, it would combine the largest and fifth-largest railroads by revenue, creating a network valued at nearly $200 billion and extending from coast to coast — an unprecedented footprint in U.S. rail history.
  • Union Pacific CEO Jim Vena has publicly discussed the strategic merits of a transcontinental railroad, and Norfolk Southern CFO Jason Zampi has echoed support for such a structure, citing potential benefits.

Markets in Motion: Turnover Gains Spark Sharper Spreads

By Geoff Howie

  • Sanli Environmental and mDR saw significant increases in average daily trading turnover, with returns of 98.9% and 137.5% respectively.
  • Q&M Dental led net institutional inflows with S$7.68 million, alongside increased CEO ownership and active share buybacks.
  • OKP Holdings secured a S$258 million contract, boosting its order book to S$736 million, with visibility to 2031.

MMC Ports Pre-IPO – Monetization Event for Promoters

By Nicholas Tan

  • MMC Port Holdings Berhad (2436494D MK) is looking to raise up to US$2bn in its upcoming Malaysian IPO.
  • It is principally involved in port operations in Malaysia. The firm operates five sea ports and a solid product jetty terminal, and conducts ship-to-ship (STS) services at an offshore port.
  • In this note, we talk about the not-so-positive aspects of the deal.

Aberdeen Extends CLINT Deemed Interest to 6%

By Geoff Howie

  • Institutions were net buyers of Singapore stocks, with a net inflow of S$113 million from July 11 to 17.
  • Aberdeen Group plc increased its interest in CapitaLand India Trust to 6.15% after acquiring over 2.5 million units.
  • United Overseas Bank led share buybacks, purchasing 1 million shares at an average price of S$36.80.

Small-Caps Positioned to Benefit from Multi-Year Defence Spending Cycle

By Atrium Research

  • What you need to know: • Defence and aerospace small-cap equities are emerging as key beneficiaries of increasing government defence budgets.
  • • Canada has committed to meeting NATO’s 2% GDP target by 2025-2026, with interim boosts totalling C$9B in new spending.
  • • Demand for fighter jets, naval systems, NORAD upgrades, and drone defence create multi-year tailwinds for niche suppliers.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Eiken Chemical, 3SBio Inc, Oxley Holdings, CSL Ltd, D.Western Therapeutics Institute Inc., Carlsmed, Immvira Bioscience, Longeveron , Merck & Co and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Japan Activism Briefs | Noritake, Square Enix, Eiken Chemical
  • 3SBio (1530 HK): Global Index Inclusion as Stock Soars
  • Markets in Motion: Turnover Gains Spark Sharper Spreads
  • CSL Limited: Initiation of Coverage- Powering Global Growth with Solid Immunoglobulin & Albumin Wins!
  • News Flash: D. Western Therapeutics Institute (4576 JP) – July 17, 2025
  • Carlsmed, Inc. (CARL): Spinal Fusion Surgery Focused Company Looking to Be Next MedTech IPO Winner
  • ImmVira (亦诺微) Pre-IPO: Niche Product, but the Indication Is Limited
  • Carlsmed (CARL US) IPO: Will Take Time to Straighten Its Spine, Can Subscribe Just for Listing Gain
  • LGVN: Company Adds to Heart Treatment Technologies
  • Merck’s $10 Billion Verona Buyout: Smart Bet or Scramble Before the Keytruda Cliff?


Japan Activism Briefs | Noritake, Square Enix, Eiken Chemical

By Mark Chadwick

  • Noritake – Despite strong profits from semiconductor ceramics, lack of strategy for underperforming segments and idle assets invites activist pressure for structural reform. 
  • Square Enix – New turnaround plan lacks clear KPIs and capital discipline, prompting activists to demand sharper execution and improved shareholder returns. 
  • Eiken Chemical – Activists gained board influence through compromise, advancing governance reform and signaling momentum toward a potential buyout.

3SBio (1530 HK): Global Index Inclusion as Stock Soars

By Brian Freitas

  • 3SBio Inc (1530 HK)‘s stock price has soared over the last couple of months, and the higher market cap should result in global index inclusion in August.
  • 3SBio Inc (1530 HK) has gone from middle/bottom of the pack to best performer among its peer group over the last two months.
  • There will be a lot of positioning in the stock, but we see a similar trend across stocks in the industry.

Markets in Motion: Turnover Gains Spark Sharper Spreads

By Geoff Howie

  • Sanli Environmental and mDR saw significant increases in average daily trading turnover, with returns of 98.9% and 137.5% respectively.
  • Q&M Dental led net institutional inflows with S$7.68 million, alongside increased CEO ownership and active share buybacks.
  • OKP Holdings secured a S$258 million contract, boosting its order book to S$736 million, with visibility to 2031.

CSL Limited: Initiation of Coverage- Powering Global Growth with Solid Immunoglobulin & Albumin Wins!

By Baptista Research

  • CSL Limited, an Australian multinational specialty biotechnology company, reported its financial performance for the first half of fiscal year 2025, presenting a nuanced picture of its current business landscape.
  • From an investor’s standpoint, analyzing both the positive aspects and the challenges noted in the earnings call gives a clearer sense of CSL Limited’s operational and strategic trajectory.
  • Starting with the positives, the company reported solid financial results, with group revenues reaching $8.5 billion, reflecting a 5% increase at constant currency.

News Flash: D. Western Therapeutics Institute (4576 JP) – July 17, 2025

By Sessa Investment Research

  • DWTI announced after the close on July 15 that it has decided to add H-1129, an in-house discovered candidate compound, to its pipeline and develop it as a treatment for corneal and conjunctival diseases caused by immune disorders.
  • ‘Corneal and conjunctival diseases’ refers to a general term for conditions characterized by inflammation or damage to the cornea and conjunctiva.
  • The cornea is the dome- shaped transparent layer covering the iris, pupil and anterior chamber, which focuses and refracts light onto the retina. 

Carlsmed, Inc. (CARL): Spinal Fusion Surgery Focused Company Looking to Be Next MedTech IPO Winner

By IPO Boutique

  • AI-Enabled personalized spine surgery solutions is set to debut on Wednesday, July 23rd.
  • Channel checks just completed, are currently revealing, according to guidance, multiple-times oversubscribed with continued long-only conversions.
  • Based on the flash numbers released in the prospectus of $12.0m in Q2 revenue, the growth for the year would be roughly 77% which are highly-attractive figures.

ImmVira (亦诺微) Pre-IPO: Niche Product, but the Indication Is Limited

By Ke Yan, CFA, FRM

  • ImmVira, a China-based clinical-stage biotech, is looking to raise at least USD 100 million via a Hong Kong listing. The joint book runners are CITI and CICC.
  • In this insight, we look at the company’s core product, MVR-T3011, including its mechanism and clinical data.
  • We also look at the company’s pre-IPO investors and management team.

Carlsmed (CARL US) IPO: Will Take Time to Straighten Its Spine, Can Subscribe Just for Listing Gain

By Tina Banerjee

  • Artificial-Intelligence-Powered spine surgery developer Carlsmed is offering 6.7M shares priced between $14 and $16 apiece. At the mid-point, the company is seeking a market value of $430M.
  • Carlsmed currently markets the aprevo Technology Platform for lumbar spine fusion surgery, and is developing aprevo for cervical spine fusion surgeries, which is expected to be commercialized in 2026.
  • Carlsmed estimates there is a total addressable market of $13.4B for aprevo in the U.S. Aprevo may also benefit other musculoskeletal applications beyond the spine, unlocking greater market potential.

LGVN: Company Adds to Heart Treatment Technologies

By Zacks Small Cap Research

  • Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer’s Disease.
  • The company announced that it has licensed a US patent from the University of Miami that has widespread therapeutic indications for heart diseases.
  • This acquisition fits in perfectly with the existing lineup and should prove beneficial to patients and shareholders.

Merck’s $10 Billion Verona Buyout: Smart Bet or Scramble Before the Keytruda Cliff?

By Baptista Research

  • Merck’s $10 billion acquisition of Verona Pharma marks another pivotal move in its broader strategy to offset the looming revenue hit from Keytruda’s patent expiration in late 2028.
  • The company is navigating an era of transformation, with nearly 20 launches planned over the next few years, including key assets in cardiometabolic, immunology, HIV, and oncology.
  • While Keytruda generated $29.5 billion in 2024 revenue and remains Merck’s crown jewel, its approaching loss of exclusivity is expected to erode annual revenues by $18 billion, prompting Merck to aggressively expand and diversify its pipeline.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Max Healthcare Institute, Sichuan Kelun-Biotech Biopharm, Lifenet Insurance Company, Reece Ltd, Vivendi SE, Anthem Biosciences, Guangzhou Automobile Group, Kawasaki Heavy Industries, Korea Stock Exchange KOSPI 200, Seven & I Holdings and more

By | Daily Briefs, Most Read

In today’s briefing:

  • NIFTY50 Index Rebalance Preview: Forecast Changes, Impact, Positioning
  • Sichuan Kelun Biotech (6990 HK): Price Surge & Global Index Inclusion
  • [Japan Index] Lifenet Insurance (7157) Super Green TOPIX Inclusion
  • Reece (REH AU): Positioning Increases as Global Index Deletion Nears
  • Vivendi: Mandatory Buyout in Motion – High-Conviction Risk Arb with 30%+ Upside
  • Anthem Biosciences IPO: Lists Today; Index Inclusion Timing
  • A/H Premium Tracker (To 18 July 2025):  “Beautiful Skew” Continues Some More
  • Kawasaki Heavy (7012 JP): Cheaper than Peers with Index Inclusion Kicker
  • Two New Tax Tweaks Set to Shake Up Korea’s Local Stock Market: Trading Tax & CGT Threshold
  • The Final ACT Comedy of Errors Opens the Way for Real Value to Emerge at Seven & I


NIFTY50 Index Rebalance Preview: Forecast Changes, Impact, Positioning

By Brian Freitas


Sichuan Kelun Biotech (6990 HK): Price Surge & Global Index Inclusion

By Brian Freitas

  • The recent placement and price surge in Sichuan Kelun-Biotech Biopharm (6990 HK) could result in the stock being added to a global index in August.
  • Sichuan Kelun-Biotech Biopharm has outperformed its peers as the entire industry has been trading well. There is a small increase in short interest in the stock.
  • Positioning has increased steadily over the last month. Momentum in the stock and its peers could lead to further upside before profit taking kicks in.

[Japan Index] Lifenet Insurance (7157) Super Green TOPIX Inclusion

By Travis Lundy

  • On Friday after the close, Lifenet Insurance Company (7157 JP) announced that it would move to TSE Prime on 25 July 2025. 
  • That means it will go into TOPIX on 29 August 2025 at the close. There is a lot to buy. Under the old Quiddity TOPIX Inclusion matrix, it’s super green.
  • It also has a very interesting shareholder structure which is worth looking at in detail.

Reece (REH AU): Positioning Increases as Global Index Deletion Nears

By Brian Freitas

  • Reece Ltd (REH AU)‘s stock price has dropped a lot over the last year, and the significantly lower market cap could result in global index deletion in August. 
  • Short interest started to pick up early this year and has accelerated over the last couple of months. There are indications of positioning in the stock.
  • Reece Ltd (REH AU) has underperformed its peers but still trades at a higher EV/EBITDA and forward PE compared to most of its peer group.

Vivendi: Mandatory Buyout in Motion – High-Conviction Risk Arb with 30%+ Upside

By Jesus Rodriguez Aguilar

  • Vivendi trades at a 37.7% discount to NAV, with a mandated buyout by Bolloré offering a realistic upside of 22–37% within six months pending French Supreme Court review.
  • The AMF has ruled that Bolloré must launch a tender offer. Vivendi’s simplified structure, anchored by UMG, enables clear valuation through a detailed SOTP showing €5.26/share NAV.
  • With liquidity exceeding €3bn, Bolloré can finance a buyout of minority shareholders. Even conservative pricing scenarios imply strong returns for arbitrage investors seeking event-driven upside.

Anthem Biosciences IPO: Lists Today; Index Inclusion Timing

By Brian Freitas

  • Anthem Biosciences raised INR 34bn (US$394m) in its IPO valuing the company at INR 320bn (US$3.7bn). The stock lists today.
  • The grey market premium is INR 132/share, so the stock could list 23.2% higher than the IPO price. That will help in getting larger index flows.
  • Anthem Biosciences could be added to one global index in November while the stock price gain will determine whether the stock is added to the other global index in December.

A/H Premium Tracker (To 18 July 2025):  “Beautiful Skew” Continues Some More

By Travis Lundy

  • AH premia flat again among liquid names but “beautiful skew” of wide premia converging more than narrow premia continues bigly. It still pays well to be long wide H discounts.
  • Weeks ago I said, “It has paid to be long the H on those H/A pairs with the biggest H discounts. I would continue to ride that trend.” Ride on.
  • The data tables below update on a daily basis in the Tools section of Smartkarma. The SOUTHBOUND Flow Monitor and AH Monitor are both there free for SK readers.

Kawasaki Heavy (7012 JP): Cheaper than Peers with Index Inclusion Kicker

By Brian Freitas

  • Kawasaki Heavy Industries (7012 JP) stock price has moved higher over the last few months, and the increased market cap should result in global index inclusion in August.
  • Kawasaki Heavy Industries (7012 JP) has underperformed its larger peers, and the stock is trading cheaper than the average of its peers on most metrics. 
  • There will be positioning in the stock that has been built up over the last month and a relative value trade could offer better risk reward here.

Two New Tax Tweaks Set to Shake Up Korea’s Local Stock Market: Trading Tax & CGT Threshold

By Sanghyun Park

  • Trading tax gradually dropped from 0.25% in 2020 to 0.15% in 2025, boosting volatility and short-term trades; a hike to 0.25% could cool momentum but widen arbitrage and basis spreads.
  • If the major shareholder tax threshold drops to ₩1B, year-end retail dumps and Jan buybacks will return—but with less wild swings and more measured short-term fade and momentum trades.
  • If the tax revamp drops end-July, expect a September Assembly push. Usually effective next January, but like 2023’s cap gains hike, changes might apply immediately in 2025.

The Final ACT Comedy of Errors Opens the Way for Real Value to Emerge at Seven & I

By Michael Causton

  • ACT’s bid for Seven & I has been withdrawn and Seven will be better off long-term because of it – although we detail here how competitors are catching up fast.
  • Once York HD has been split off, the company can at last focus on its crucial local CVS operation: Japan makes up 25% of revenues but almost 50% of profits.
  • The potential is real and we are bullish on the long-term value but we would have been more bullish if the former CEO Ryuichi Isaka was still on board.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Consumer: Guangzhou Automobile Group, Seven & I Holdings, Meituan, CJ Corp, Cocoa Futures, Central Plaza Hotel, NIQ Global Intelligence, Shanghai Jin Jiang International Hotels, JB Hi-Fi Ltd and more

By | Consumer, Daily Briefs

In today’s briefing:

  • A/H Premium Tracker (To 18 July 2025):  “Beautiful Skew” Continues Some More
  • Crime Scene Investigation: How Seven&I (3382-JP) Murdered the ACT (ATD-CA) Deal
  • The Final ACT Comedy of Errors Opens the Way for Real Value to Emerge at Seven & I
  • HK Connect SOUTHBOUND Flows (To 18 July 2025); Volumes Strong, Net Buying Decent, Meituan Hot
  • Korea Surpasses France as Top Exporter of Cosmetics to the USA [CJ Olive Young – Key Beneficiary]
  • Global Commodities: Cocoa market crunch
  • Quiddity Leaderboard SET50 Dec25: Capping Flows in September and Index Changes in December
  • NIQ Global Intelligence Plc (NIQ): Advent-Backed IPO to Provide Litmus Test for Market
  • Pre-IPO Shanghai Jin Jiang International Hotels – The Pain Points and the Outlook
  • JB Hi-Fi Limited: Initiation of Coverage- Why Its Recent Growth In Tech & Appliance Sales Is Just the Beginning!


A/H Premium Tracker (To 18 July 2025):  “Beautiful Skew” Continues Some More

By Travis Lundy

  • AH premia flat again among liquid names but “beautiful skew” of wide premia converging more than narrow premia continues bigly. It still pays well to be long wide H discounts.
  • Weeks ago I said, “It has paid to be long the H on those H/A pairs with the biggest H discounts. I would continue to ride that trend.” Ride on.
  • The data tables below update on a daily basis in the Tools section of Smartkarma. The SOUTHBOUND Flow Monitor and AH Monitor are both there free for SK readers.

Crime Scene Investigation: How Seven&I (3382-JP) Murdered the ACT (ATD-CA) Deal

By Michael Allen

  • Alimentation Couche-Tard just withdrew their offer to buy Seven&i for $47.2bn, and within two days, Seven’s share price is down 12.5% and ACT’s is up 10.6%.
  • Seven’s management deluded itself into thinking it could match ACT’s returns by selling off non-core assets. This is pure financial gimmickry, and the market sees right through it.
  • Seven will never see a deal as good as the one ACT offered, and failing to capitalize on should be investigated as a potential crime against common sense.

The Final ACT Comedy of Errors Opens the Way for Real Value to Emerge at Seven & I

By Michael Causton

  • ACT’s bid for Seven & I has been withdrawn and Seven will be better off long-term because of it – although we detail here how competitors are catching up fast.
  • Once York HD has been split off, the company can at last focus on its crucial local CVS operation: Japan makes up 25% of revenues but almost 50% of profits.
  • The potential is real and we are bullish on the long-term value but we would have been more bullish if the former CEO Ryuichi Isaka was still on board.

HK Connect SOUTHBOUND Flows (To 18 July 2025); Volumes Strong, Net Buying Decent, Meituan Hot

By Travis Lundy

  • Gross SOUTHBOUND volumes again US$17+bn a day this past 5-day week. Net buying strong at +US$550mm a day. Meituan the top buy extending a very strong 12 week run.
  • Among the top buys as a percentage of volume, FINANCIALS stood out, dramatically. Again. INFO TECH negative again after two weeks of buying broke a three-month sell streak.
  • The data tables below update on a daily basis in the Tools section of Smartkarma. The SOUTHBOUND Flow Monitor and AH Monitor are both there free for SK readers.

Korea Surpasses France as Top Exporter of Cosmetics to the USA [CJ Olive Young – Key Beneficiary]

By Douglas Kim

  • Korea surpassed France as the top exporter of cosmetics to the USA in 2024. Korea exported $1.7 billion worth of cosmetics to the USA in 2024, up 54.2% YoY.
  • CJ Olive Young’s online cosmetic sales to overseas markets soared 70% YoY in 1H 2025, fueled largely by the explosive demand from the United States.
  • We have raised our NAV valuation of CJ Corp to 207,713 won per share (up 28%). We raised the valuation of CJ Olive Young to 7 trillion won. 

Global Commodities: Cocoa market crunch

By At Any Rate

  • Concerns for sugar cane yields and sugar content in major sugar market exporter
  • China’s soybean import demand reached record seasonal high, following Brazilian crop
  • Short covering seen in grain complex, USDA trimmed US corn availability expectations, driving force behind corn price recovery; tariff impacts on Brazilian products into US market, potential changes in sweetener mix for Coca Cola

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Quiddity Leaderboard SET50 Dec25: Capping Flows in September and Index Changes in December

By Janaghan Jeyakumar, CFA

  • The SET50 index tracks the performance of the top 50 largest and most liquid names listed on the Stock Exchange of Thailand (SET).
  • In this insight, we take a look at our capping flow expectations for the September 2025 index rebal event.
  • We have also presented our index change expectations for the next semiannual index review in December 2025 (regular ADDs/DELs only take place in June and December).

NIQ Global Intelligence Plc (NIQ): Advent-Backed IPO to Provide Litmus Test for Market

By IPO Boutique

  • The company that describes itself as a leading global consumer intelligence company positioned at the nexus of brands, retailers and consumers is to debut on Wednesday, July 23rd.
  • According to guidance, that the deal is multiple-times oversubscribed with long-only, 1-on-1 conversions including anchor indications.
  • The company showed solid growth in 2024 of nearly 19% and followed that up with solid flash numbers of +7.5% growth in Q2.

Pre-IPO Shanghai Jin Jiang International Hotels – The Pain Points and the Outlook

By Xinyao (Criss) Wang

  • In 25Q1, Jin Jiang did not show a turning point in performance.There’s uncertainty about whether 2025 performance target can be achieved due to low efficiency of membership system/weak overseas business.
  • The growth of the core mid-to-low end economic market is weak.The transition to the high-end market or international expansion is difficult to shoulder the banner of growth in short term.
  • Valuation of Jin Jiang could be lower than Atour and H World Group, who have found new development paths and growth points.A relatively conservative valuation range is P/E of 15-18x.

JB Hi-Fi Limited: Initiation of Coverage- Why Its Recent Growth In Tech & Appliance Sales Is Just the Beginning!

By Baptista Research

  • JB Hi-Fi Limited has presented a mixed financial performance for the first half of the 2025 fiscal year, showcasing its resilience in a competitive and challenging retail environment.
  • The company reported a solid increase in total sales across its key divisions, namely JB Hi-Fi Australia, JB Hi-Fi New Zealand, and The Good Guys.
  • Total sales in JB Hi-Fi Australia grew by 7.2%, reaching AUD 3.88 billion, while JB Hi-Fi New Zealand exceeded expectations with a 20% rise in sales to NZD 202.5 million.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Reece Ltd, Hub24 Ltd, Next Science Ltd, Waypoint REIT, Provaris Energy , Netwealth Group , Regis Resources and more

By | Australia, Daily Briefs

In today’s briefing:

  • Reece (REH AU): Positioning Increases as Global Index Deletion Nears
  • Relative Value Opportunities in Asia-Pac, Pair Trade Roundup.
  • Asset Sales, Mergers, and Regulatory Developments: Key Updates from SSI Weekly Newsletter
  • Waypoint REIT (WPR AU) Vs. Region Group (RGN AU): Aussie REIT Spread Trade Looks Ripe
  • Provaris Energy (ASX:PV1) RaaS Interview Transcript 21 July 2025
  • Netwealth (NWL AU) Vs. Hub24 (HUB AU): Can Netwealth Catch Up to Hub24’s Momentum?
  • Regis Resources Ltd – The Monday Report – 21 July 2025


Reece (REH AU): Positioning Increases as Global Index Deletion Nears

By Brian Freitas

  • Reece Ltd (REH AU)‘s stock price has dropped a lot over the last year, and the significantly lower market cap could result in global index deletion in August. 
  • Short interest started to pick up early this year and has accelerated over the last couple of months. There are indications of positioning in the stock.
  • Reece Ltd (REH AU) has underperformed its peers but still trades at a higher EV/EBITDA and forward PE compared to most of its peer group.

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup.

By Gaudenz Schneider

  • Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.
  • Highlight: Three Aussie pair trade opportunities across three sectors persist.
  • Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.

Asset Sales, Mergers, and Regulatory Developments: Key Updates from SSI Weekly Newsletter

By Special Situation Investments

  • Next Science (NXS:AX) plans a large capital return after selling assets to Demetra Holdings, with a 13% spread to expected distribution.
  • Cantor Equity Partners I (CEPO) merges with BSTR, becoming a major Bitcoin treasury, exiting with a 17% gain.
  • Banxa’s (BNXA:V) spread widens to 30% amid shareholder sales and pending acquisition by OSL Group, with Genius Act tailwinds.

Waypoint REIT (WPR AU) Vs. Region Group (RGN AU): Aussie REIT Spread Trade Looks Ripe

By Gaudenz Schneider

  • Context: The Region (RGN AU) vs. Waypoint REIT (WPR AU) Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.
  • Highlights: The pair shows strong alignment in both statistical terms and fundamental metrics and factors.
  • Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.

Provaris Energy (ASX:PV1) RaaS Interview Transcript 21 July 2025

By Research as a Service (RaaS)

  • RaaS Research’s Finola Burke and Andrew Williams interview Provaris Energy Managing Director/CEO Martin Carolan on the company’s strategy, its partnerships with Yinson and K Line and path to a FID.

Netwealth (NWL AU) Vs. Hub24 (HUB AU): Can Netwealth Catch Up to Hub24’s Momentum?

By Gaudenz Schneider

  • Context: The Netwealth (NWL AU) vs. Hub24 (HUB AU) Price-Ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.
  • Highlights: The two companies share very similar business models and target markets. While they are closely correlated, their current price momentum is a factor when considering relative value trades.
  • Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.

Regis Resources Ltd – The Monday Report – 21 July 2025

By FNArena

  • Wrap of events affecting the market on Friday night and the weekend and a preview of the week ahead

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Tokai Carbon, Resonac Holdings , Ono Pharmaceutical, TSE Tokyo Price Index TOPIX and more

By | Daily Briefs, Japan

In today’s briefing:

  • Tokai Carbon (5301.T) – Portfolio Shift Underway; Margin Recovery Key to Re-Rating
  • Resonac Holdings (TSE: 4004) – Strategic Pivot Toward Semiconductor Materials
  • Ono Pharmaceutical (4528 JP): Label Expansion Helps, But Long-Term Growth Momentum Calls for More
  • Rather than “Technical Guidance,” What Is Needed Is Thorough Fiduciary Duty to Shareholders


Tokai Carbon (5301.T) – Portfolio Shift Underway; Margin Recovery Key to Re-Rating

By Rahul Jain

  • Revenue peaked in FY23 but margins have declined due to cost pressures and impairments.
  • The company is exiting underperforming assets and expanding in fine carbon, furnaces, and carbon black.
  • At ¥1,010, it trades at ~19.6x FY25e P/E, in line with peers but below book at 0.8x P/B.

Resonac Holdings (TSE: 4004) – Strategic Pivot Toward Semiconductor Materials

By Rahul Jain

  • Past Performance: Revenues stable; margins improved due to semiconductor growth, despite weak performance in legacy chemicals and graphite electrodes.
  • Strategy & Shutdown: Shutting 30% electrode capacity; refocusing on high-margin semiconductor, SiC, and packaging materials with ¥330 bn capex planned by FY25.
  • Valuation: Trades at 8x EV/EBITDA and 14x P/E FY25E; re-rating possible with higher margins and semiconductor mix.

Ono Pharmaceutical (4528 JP): Label Expansion Helps, But Long-Term Growth Momentum Calls for More

By Tina Banerjee

  • Ono Pharmaceutical (4528 JP) guided Opdivo revenue in FY26 to be ¥138.5B (Japan: ¥125B, up 4% and Overseas: ¥13.5B, up 3%), up 4% YoY.
  • Opdivo in combination with Yervoy (from Bristol Myers Squibb) was approved in Europe, US, South Korea, and Japan for the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.
  • In FY26, Opdivo’s revenue growth will come from indication expansion but smaller addressable patient population remains a concern for long term.

Rather than “Technical Guidance,” What Is Needed Is Thorough Fiduciary Duty to Shareholders

By Aki Matsumoto

  • While very few companies allocate cash appropriately, many companies simply announce small-scale share buybacks, resulting in cash being used in a half-hearted manner for both growth and shareholder returns.
  • The problem is that many managers lack awareness of their fiduciary responsibility to make sincere decisions on cash allocation based on the idea that free cash flow belongs to shareholders.
  • Even for listed companies, the time has come to discuss the role of managers who are unable to thoroughly fulfill their fiduciary duties to shareholders.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: SK Hynix, Kakaopay and more

By | Daily Briefs, South Korea

In today’s briefing:

  • SK Hynix Single-Stock ETF Scheduled for 3Q: Watch for a Repeat of the Samsung ETF Playbook
  • Kakao Pay’s Unique Quick-Flip EB: Watch Hedges & Rolls for Trading Angle


SK Hynix Single-Stock ETF Scheduled for 3Q: Watch for a Repeat of the Samsung ETF Playbook

By Sanghyun Park

  • When the SK Hynix ETF drops, expect meaningful physical buying shaking up supply-demand. Arb desks and alpha shops could pile in early, pushing the stock higher on flow.
  • Going long Hynix near listing could pay off if demand mirrors Samsung’s—ETF flows, NAV arb, and delta hedging drove a 4% jump with a noticeable increase in program buying.
  • Get in around the listing, watch flows, and take profits quickly. This is a short 2–3 day tactical play, with sharper front-running expected based on the Samsung ETF template.

Kakao Pay’s Unique Quick-Flip EB: Watch Hedges & Rolls for Trading Angle

By Sanghyun Park

  • This Kakao Pay EB deal is basically a quick block trade with immediate share exchange and a 90–102% strike price, letting them sell shares quietly with a built-in discount.
  • Korea’s seen many EBs, but Kakao Pay’s quick-flip, discount deal is really unique. Watch hedging and roll activity—timing these can capture the sell-off and unwind bounce.
  • Goldman’s sell-down triggers initial short covering and price bumps; new buyers then short, causing a second wave. Near exchange, more covering leads to choppy, drawn-out price swings.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Copper, Shoulder Innovations and more

By | Daily Briefs, United States

In today’s briefing:

  • Bullish Copper: Comex-LME Spreads Off The Charts + Positive China TSF Data
  • Shoulder Innovations IPO Preview: Seeing Value In InSet Glenoid Technology and Disruptive Ecosystem


Bullish Copper: Comex-LME Spreads Off The Charts + Positive China TSF Data

By Sameer Taneja

  • In our previous insight, Trump 50% Import Tariff Could Send Copper Into Stratosphere Short-Term: LME Can Breach 11k USD/Ton, we highlighted upside risk to the LME price.
  • Comex-LME spreads remain elevated at $ 2,500/ton levels, reflecting the impact of tariffs that haven’t yet been imposed, amid ongoing supply disruptions. Inventories, though, have stopped depleting on the LME. 
  • We remain bullish on copper in the countdown to August 1st, where it is likely that tariffs of 50% are imposed on copper. 

Shoulder Innovations IPO Preview: Seeing Value In InSet Glenoid Technology and Disruptive Ecosystem

By Andrei Zakharov

  • Shoulder Innovations Inc., high-growth and pure-play shoulder arthroplasty device company, filed for an IPO in the United States.
  • Their flagship product, InSet Glenoid, is the first and only FDA cleared device that solves glenoid loosening. The company has raised ~$115M in equity according to the S-1.
  • I believe there is good near-term visibility for growth as Shoulder Innovations drives commercial expansion and achieves greater domestic reach.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: Max Healthcare Institute, Anthem Biosciences, JSW Steel Ltd and more

By | Daily Briefs, India

In today’s briefing:

  • NIFTY50 Index Rebalance Preview: Forecast Changes, Impact, Positioning
  • Anthem Biosciences IPO: Lists Today; Index Inclusion Timing
  • JSW Steel (NSE: JSWSTEEL) – Strong Q1 Beat, Confident FY26 Guidance, Premium Valuation


NIFTY50 Index Rebalance Preview: Forecast Changes, Impact, Positioning

By Brian Freitas


Anthem Biosciences IPO: Lists Today; Index Inclusion Timing

By Brian Freitas

  • Anthem Biosciences raised INR 34bn (US$394m) in its IPO valuing the company at INR 320bn (US$3.7bn). The stock lists today.
  • The grey market premium is INR 132/share, so the stock could list 23.2% higher than the IPO price. That will help in getting larger index flows.
  • Anthem Biosciences could be added to one global index in November while the stock price gain will determine whether the stock is added to the other global index in December.

JSW Steel (NSE: JSWSTEEL) – Strong Q1 Beat, Confident FY26 Guidance, Premium Valuation

By Rahul Jain

  • Recent Results: Q1 EBITDA surged 38% YoY to ₹7,576 Cr, driven by volume ramp-up, improved product mix, and lower coking coal costs.
  • FY26 Guidance: Company maintains production at 30.5 mt and sales at 29.2 mt, reflecting confidence in its ramp-up and downstream expansion roadmap.
  • Valuation & Growth: Trading at ~18× FY27E P/E and ~7× EV/EBITDA—above global peers—justified by projected 20% EBITDA and 23% EPS growth into FY27.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: BYD, Pop Mart International Group L, Sichuan Kelun-Biotech Biopharm, Dickson Concepts Intl, ENN Energy, 52TOYS Development, Bright Smart Securities, Tencent and more

By | China, Daily Briefs

In today’s briefing:

  • Curator’s Cut: Japan Insurers Vs Banks, the State of the Chinese EV Sector and Asian Ports in Focus
  • Quiddity Leaderboard Hang Seng Index Sep25: BeOne, TME, and Pop Mart Among Our Top Picks
  • Sichuan Kelun Biotech (6990 HK): Price Surge & Global Index Inclusion
  • Dickson Concept (113 HK): More Minority Teeth Bared As Another Scheme Fails
  • Merger Arb Mondays (21 Jul) – ENN Energy, HEC Pharma, Shibaura, Abacus Storage, Insignia, Zeekr
  • Pre-IPO 52TOYS Development – The Business Model and the Concerns Behind
  • Bright Smart (1428 HK): Valuation Update
  • ECM Weekly (21 July 2025) – Muyuan, Unisplendour, NTT, Kasumigaseki, Anthem, Leads, SBI, Ascentage


Curator’s Cut: Japan Insurers Vs Banks, the State of the Chinese EV Sector and Asian Ports in Focus

By Pranav Rao

  • Welcome to Curator’s Cut, a fortnightly roundup of standout themes from the 1,000+ insights published in the past two weeks on Smartkarma
  • In this cut, we compare Japanese insurers versus banks, look at the Chinese EV sector and explore how tariff hikes benefit Asian port operators
  • Want to dig deeper? Comment or message with the themes you’d like to see highlighted next

Quiddity Leaderboard Hang Seng Index Sep25: BeOne, TME, and Pop Mart Among Our Top Picks

By Janaghan Jeyakumar, CFA

  • The Hang Seng Index is the main benchmark index for Hong Kong stocks. It follows a highly-subjective selection process which makes it difficult to predict index changes.
  • In this insight, we take a look at a group of names with reasonably high likelihood of being involved in index changes during the next review in September 2025.
  • The index changes are expected to be confirmed on 22nd August 2025.

Sichuan Kelun Biotech (6990 HK): Price Surge & Global Index Inclusion

By Brian Freitas

  • The recent placement and price surge in Sichuan Kelun-Biotech Biopharm (6990 HK) could result in the stock being added to a global index in August.
  • Sichuan Kelun-Biotech Biopharm has outperformed its peers as the entire industry has been trading well. There is a small increase in short interest in the stock.
  • Positioning has increased steadily over the last month. Momentum in the stock and its peers could lead to further upside before profit taking kicks in.

Dickson Concept (113 HK): More Minority Teeth Bared As Another Scheme Fails

By David Blennerhassett



Pre-IPO 52TOYS Development – The Business Model and the Concerns Behind

By Xinyao (Criss) Wang

  • For IP toy, the ability to provide a variety of categories is valuable,which means brands have access to diverse/creative designs/production based on IP characteristics, highlighting/interpreting the core of each IP.
  • Driven by top-tier licensed IPs, 52TOYS achieved solid growth, but its revenue scale/profit margin are inferior to peers. Due to intense competition, 52TOYS’s market share may be further squeezed.
  • The post-money valuation after Series C+ Financing is RMB4.27 billion. Based on the analysis, we think valuation of 52TOYS should be lower than Pop Mart (9992 HK), Bloks (325 HK).

Bright Smart (1428 HK): Valuation Update

By Osbert Tang, CFA

  • Bright Smart Securities (1428 HK) rallied by 132% since our last Insight, fueled by the euphoria in the brokerage and securities sector on the HK government’s stablecoin initiative.
  • At HK$16.44, it is at 100% PER premium to the sector average, ex-Guotai Junan International (1788 HK). The risk-reward payoff now looks less attractive.
  • It also implies net profit to grow by 150% by FY31F and priced at 18x PER. This appears stretched in the near term, though long-term prospects stay decent. 

ECM Weekly (21 July 2025) – Muyuan, Unisplendour, NTT, Kasumigaseki, Anthem, Leads, SBI, Ascentage

By Sumeet Singh

  • Aequitas Research’s weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
  • On the IPO front, filings and listings have cooled off going into the general summer lull.
  • On the placements front, State Bank Of India (SBIN IN) pulled the trigger on its long touted QIP.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars